Australian Operations
Include All CSL Sites

Palexia® SR

Tapentadol (as hydrochloride) sustained release

Palexia® SR is an analgesic indicated for the management of moderate to severe chronic pain unresponsive to non-narcotic analgesia.
This product is available only with a doctor’s prescription.

Who is this information for?
This information is relevant in Australia and is intended for people who have been prescribed this product or health care professionals.

Consumer Medicine Information
The Consumer Medicine Information (CMI) is a leaflet written for consumers. The CMI contains information about the medicine including:
  • What this product is used for
  • How it works
  • How this product is given
  • Side effects
Palexia SR Consumer Medicine Information (PDF, 0.20MB)

Product Information
Product Information contains information to ensure the safe and effective use of a medicine. This document is approved by the Therapeutic Goods Administration and made available by Seqirus for you if you are a:
  1. qualified healthcare professional; or
  2. consumer, provided you have read the Consumer Medicine Information for the product; want further information on the product; and agree to consult with your healthcare professional if you have any questions in relation to the Product Information.
Palexia SR Product Information (PDF, 0.20MB)

Palexia® is a registered trademark of Grunenthal GmbH, used under licence.
Palexia® is distributed by Seqirus (Australia) Pty Ltd under license from Grunenthal GmbH.

Last Updated: 13-09-2019
LinkedIn Twitter Facebook Google+
© 2019 Seqirus